Landos Biopharma (LABP) Peer Comparison

$22.91

$0.11 (0.50%)

As on 23-May-2024 16:37EDT

Market cap

$72 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

2.1

Div. Yield

0 %

Edit

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
Market cap ($ Mln)	72	2,213	6
Revenue ($ Mln)	--	175	0
Net Profit ($ Mln)	-24.80	-190.42	-6.16
Net Margin (%)	--	-106.30	-4,436.70
RoE (%)	-81.55	-54.58	-15.18
Price to Earnings	--	--	--
Price-To-Book	2.11	7.00	1.87

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
Operating Revenue	0.00	174.91	0.14
Cost of Revenue	0.00	6.93	0.07
Gross Profit	--	159.62	-0.03
Operating Expenses	25.24	374.53	20.91
Operating Profit (EBIT)	-25.24	-206.55	-20.93
Other Income	0.00	4.21	0.00
Profit before Tax	-24.80	-189.99	-21.02
Provision for Tax	0.45	-0.03	-14.86
Profit after Tax (Net Income)	-24.80	-190.42	-6.16
Minority Interest	0.00	0.00	0.00
Consolidated Profit	-3.92	-48.56	0.00

Liabilities ($ Mln)

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
Shareholder's Funds	23.15	316.05	77.86
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	0.00	21.45	7.10
Current Liabilities	6.74	83.43	6.17
Total Liabilities	38.04	473.57	6.88

Assets ($ Mln)

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
Non-Current Assets	0.00	70.99	83.64
Current Assets	29.90	349.94	7.49
Total Assets	38.04	473.57	6.88
Total Debt*	0.00	25.02	6.98
Net Current Assets	23.15	266.51	1.32

Cashflow ($ Mln)

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
Cash From Operating Activities	-20.48	-146.70	-12.38
Cash Flow from Investing Activities	--	--	--
Cash from Financing Activities	13.57	152.00	15.23
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
ROCE (%)	-61.86	-52.15	-392.15
ROE (%)	-81.55	-54.58	-15.18
ROA (%)	-53.92	-33.49	-11.68
EBIT Margin (%)	--	-118.35	-15,087.22
Net Margin (%)	--	-106.30	-4,436.70
Cash Profit Margin (%)	--	0.00	-0.13

Growth Ratios

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
Revenue Growth (%)	--	26.51	--
EBIT Growth (%)	66.02	-8.78	-184.52
Net Profit Growth (%)	13.70	-7.87	42.99
EPS Growth (%)	39.58	2.78	--
Book Value Growth (%)	-48.57	-31.49	--

Valuation Ratios

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
Price / Earnings	-1.04	-7.03	--
Price / Book Value	0.71	3.91	--
Dividend Yield (%)	--	--	--
EV/EBITDA	0.65	-5.17	0.18
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
Debt to Equity	0.00	0.00	0.08
Short term debt to equity ratio	0.00	0.01	0.01
Current Ratio	4.43	4.19	1.21
Quick Ratio	4.43	3.94	1.21
Interest Coverage	-13.08	-51.08	-262.77

Operating Efficiency Ratios

	Landos Biopharma (LABP)	Deciphera Pharmaceuticals LLC (DCPH)	First Wave BioPharma (FWBI)
Debtors to sales (%)	--	18.69	0.00
Asset Turnover	0.00	0.31	0.00
Receivable days	--	60.80	--
Inventory Days	--	2,044.06	--
Payable days	--	2,206.38	7,949.79
Cash Conversion Cycle	--	-101.52	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly